IMPROVING THE HAFNIA-BASED RESISTIVE RANDOM-ACCESS MEMORY THROUGH MATERAL ENGINEERING

Ph.DDOCTOR OF PHILOSOPH

DialogXL: All-in-One XLNet for Multi-Party Conversation Emotion Recognition

This paper presents our pioneering effort for emotion recognition in conversation (ERC) with pre-trained language models. Unlike regular documents, conversational utterances appear alternately from different parties and are usually organized as hierarchical structures in previous work. Such structures are not conducive to the application of pre-trained language models such as XLNet. To address this issue, we propose an all-in-one XLNet model, namely DialogXL, with enhanced memory to store longer historical context and dialog-aware self-attention to deal with the multi-party structures. Specifically, we first modify the recurrence mechanism of XLNet from segment-level to utterance-level in order to better model the conversational data. Second, we introduce dialog-aware self-attention in replacement of the vanilla self-attention in XLNet to capture useful intra- and inter-speaker dependencies. Extensive experiments are conducted on four ERC benchmarks with mainstream models presented for comparison. The experimental results show that the proposed model outperforms the baselines on all the datasets. Several other experiments such as ablation study and error analysis are also conducted and the results confirm the role of the critical modules of DialogXL.Comment: Accepted by AAAI 2021 main conferenc

The role of IgG N-galactosylation in spondyloarthritis

Spondyloarthritis (SpA) is a group of chronic inflammatory arthritic diseases causing inflammatory back pain and stiffness, leading to irreversible damage of joint and spine, seriously affecting the quality of life. However, the exact pathogenesis of SpA is still unknown, although the blockers of tumor necrosis factor (TNF) are a major therapeutic advance. Of interest is the association between SpA and Immunoglobulin G (IgG) N-glycosylation. IgG N-glycosylation is a process of post-translational modification (PTM) that takes part in regulating anti- and pro-inflammatory effects. A relationship between IgG N-glycosylation and the development of inflammatory arthritic diseases exists, in addition this relationship often occurs before the onset of disease. There are studies reporting the association between IgG N-glycosylation and SpA, leading to a significant amount of data being generated. Analysis of this data in a rigorous form is greatly needed, hence this review will focus on identifying the relationships that exist between IgG N-glycosylation in inflammatory arthritis. More specifically, the modification to the structure of IgG N-glycosylation via TNF blockers as a treatment, the link between disease activity and IgG N-glycosylation, and the predictive capacity of IgG N-glycosylation in SpA. Investigation of IgG N-glycosylation has demonstrated that IgG N-galactosylation plays an important role in the development and prognosis of SpA. This association provides a novel pathway to further research to improve early diagnosis and possible biomarkers for treatment of patients with SpA

The progress and prospect of sentinel lymph node mapping in endometrial carcinoma

Sentinel lymph node (SLN) refers to the initial site of the lymphatic drainage from a primary tumor area. Identifying the SLN and analyzing tumor involvement can predict the status of the remaining lymph nodes. Accordingly, sentinel lymph node mapping (SLN mapping) has been brought up and widely applied to cancer therapy for its illuminating role in clinical lymph node resection. Sufficient information to guide surgical pathological staging and adjuvant treatment in endometrial cancer can be rendered by SLN mapping, hence minimizing surgery injury and reducing the incidence of complications. Evidence suggests that using SLN mapping does not affect progression-free survival (PFS) and overall survival (OS) of endometrial cancer patients. Furthermore, there is increasing evidence that using SLN mapping has a high detection rate (DR), sensitivity, and negative predictive value (NPV) for patients with early-stage lower-risk endometrial cancer. This review aims to systematically summarize the advances and application prospects of SLN mapping in endometrial cancer, with an expectation of furnishing reference for the clinical application

First identification of long non-coding RNAs in fungal parasite Nosema ceranae

International audienceAbstractNosema ceranae is a unicellular fungal parasite of honey bees and causes huge losses for apiculture. Until present, no study on N. ceranae long non-coding RNAs (lncRNAs) was documented. Here, we sequenced purified spores of N. ceranae using strand-specific library construction and high-throughput RNA sequencing technologies. In total, 83 novel lncRNAs were predicted from N. ceranae spore samples, including lncRNAs, long intergenic non-coding RNAs (lincRNAs), and sense lncRNAs. Moreover, these lncRNAs share similar characteristics with those identified in mammals and plants, such as shorter length and fewer exon number and transcript isoforms than protein-coding genes. Finally, the expression of 12 lncRNAs was confirmed with RT-PCR, confirming their true existence. To our knowledge, this is the first evidence of lncRNAs produced by a microsporidia species, offering novel insights into basic biology such as regulation of gene expression of this widespread taxonomic group

The mutation in splicing factor genes correlates with unfavorable prognosis, genomic instability, anti-tumor immunosuppression and increased immunotherapy response in pan-cancer

Splicing abnormality resulting from somatic mutations in key splicing factor genes (SFG) has been detected in various cancers. Hence, an in-depth study of splicing factor genes mutations’ impact on pan-cancer is meaningful. This study investigated associations of splicing factor genes mutations with clinical features, tumor progression phenotypes, genomic integrity, anti-tumor immune responses, and immunotherapy response in 12 common cancer types from the TCGA database. Compared to SFG-wildtype cancers, SFG-mutated cancers displayed worse survival prognosis, higher tumor mutation burden and aneuploidy levels, higher expression of immunosuppressive signatures, and higher levels of tumor stemness, proliferation potential, and intratumor heterogeneity (ITH). However, splicing factor genes-mutated cancers showed higher response rates to immune checkpoint inhibitors than splicing factor genes-wildtype cancers in six cancer cohorts. Single-cell data analysis confirmed that splicing factor genes mutations were associated with increased tumor stemness, proliferation capacity, PD-L1 expression, intratumor heterogeneity, and aneuploidy levels. Our data suggest that the mutation in key splicing factor genes correlates with unfavorable clinical outcomes and disease progression, genomic instability, anti-tumor immunosuppression, and increased immunotherapy response in pan-cancer. Thus, the splicing factor genes mutation is an adverse prognostic factor and a positive marker for immunotherapy response in cancer